---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-25-000070"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:45:17.229358+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amgen Q3 revenue up 12% to $9.6B, GAAP EPS $5.93, non-GAAP EPS $5.64

## Summary
- Revenue $9.6B (+12% YoY), product sales growth 12% on 14% volume growth, partially offset by 4% lower net price.
- GAAP EPS $5.93 (+14% YoY), includes $400M Otezla intangible asset impairment charge.
- Non-GAAP EPS $5.64 (+1% YoY); non-GAAP operating margin 47.1%, down 2.5 ppt.
- Free cash flow $4.2B vs $3.3B in Q3 2024, driven by working capital timing and lower interest.
- Sixteen products delivered double-digit sales growth including Repatha, EVENITY, TEZSPIRE, and BLINCYTO.

## SEC filing metadata
- accession: 0000318154-25-000070
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/0000318154-25-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-25-000070
- JSON: https://secwatch.observer/filing/0000318154-25-000070.json
- Plain text: https://secwatch.observer/filing/0000318154-25-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.